LONDON (AFX) - SR Pharma plc said the European Patent Office has granted the company its core RNAi patent for the company’s compounds which form the basis of its therapeutic development pipeline focused on cancer indications.
LONDON (AFX) - SR Pharma plc said the European Patent Office has granted the company its core RNAi patent for the company’s compounds which form the basis of its therapeutic development pipeline focused on cancer indications.
